Zwitterionic Nanofiber Encapsulation Membranes for Islet Cell Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current encapsulation devices for islet transplantation in Type 1 diabetes suffer from mechanical weakness, limited mass delivery, and fibrotic growth, posing safety concerns and hindering long-term functionality and retrieval.

Innovation Solution

Development of zwitterionic polyurethane (ZPU) nanofibrous membranes with a positively charged zwitterionic moiety backbone, which are electrospun to create a mechanically robust, hydrophilic, and antifouling encapsulation device that prevents cell escape and induces minimal cellular deposition.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If hydrogel-based macroscopic devices (alginate, PEG) are used for encapsulation, then biocompatibility and high diffusion rates are achieved, but mechanical strength is relatively low and cell escape risk increases

Engineering Contradiction:
Improvebiocompatibility and diffusion rateVSAvoidmechanical strength
Core Design Contradiction:
ReliabilityVSStrength

Solution Approach 1:

The patent employs composite materials by combining zwitterionic polymers (which provide biocompatibility and antifouling properties) with polyurethane or nylon backbones (which provide mechanical strength). This composite structure allows the material to simultaneously achieve high biocompatibility, excellent mass delivery, and robust mechanical properties, resolving the contradiction between soft hydrogel-like performance and structural integrity.

Inventive Principle:
Principle #40Composite materials

Solution Approach 2:

The patent modifies the chemical structure of polyurethane and nylon by incorporating zwitterionic moieties, changing the material parameters to achieve both mechanical robustness and biocompatibility. The zwitterionic modification transforms the surface properties to be highly hydrophilic and antifouling while maintaining the bulk mechanical strength of the polymer matrix.

Inventive Principle:
Principle #35Parameter changes

2Strength

If hydrophobic macroscopic devices (PTFE, PCL) are used, then mechanical robustness and cell escape prevention are improved, but fibrotic growth around devices increases and mass delivery is constrained

Engineering Contradiction:
Improvemechanical robustnessVSAvoidfibrotic growth and mass delivery constraint
Core Design Contradiction:
StrengthVSObject-affected harmful factors

Solution Approach 1:

The patent fundamentally changes the surface chemistry parameter of the polyurethane/nylon device by incorporating zwitterionic groups, transforming it from a hydrophobic surface to a highly hydrophilic, antifouling surface. This parameter change eliminates fibrotic growth while preserving the mechanical robustness and mass delivery capabilities of the polyurethane/nylon matrix.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent converts the typically problematic interaction between hydrophobic device surfaces and biological tissues (which causes fibrosis) into a beneficial antifouling effect by introducing zwitterionic moieties. The zwitterionic surface actively repels protein adsorption and cellular adhesion, preventing fibrotic encapsulation while maintaining device functionality.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Strength

If conventional polyurethane is used for encapsulation, then mechanical strength is achieved, but mass delivery is constrained due to hydrophobic nature

Engineering Contradiction:
Improvemechanical strengthVSAvoidmass delivery
Core Design Contradiction:
StrengthVSQuantity of substance

Solution Approach 1:

The patent changes the hydrophobicity parameter of polyurethane by incorporating zwitterionic groups, transforming it into a highly hydrophilic material. This parameter change dramatically improves mass delivery of glucose, insulin, and other therapeutic molecules while preserving the mechanical strength provided by the polyurethane backbone structure.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The ZPU device ensures adequate mass delivery, maintains mechanical robustness, prevents cell entry and escape, and supports long-term functionality with minimal foreign body response, effectively managing diabetes for up to 3 months in diabetic mice.

Implementation Method 1

the one or more biocompatible polymers have a backbone including a positively charged component of a zwitterionic moiety

Methodology Applied
Scientific EffectElectrostatic repulsion: Ion Repulsion/Attraction

Implementation Method 2

which are electrospun to create a mechanically robust, hydrophilic, and antifouling encapsulation device

Methodology Applied
Scientific EffectElectrospinning: Electrohydrodynamics

Implementation Method 3

The ZPU device ensures adequate mass delivery

Methodology Applied
Scientific EffectDiffusion: Diffusion

Data Source

PatentEP3963326B1Fibers of polymers that have a backbone including a positively charged component of a zwitterionic moiety
Publication Date: 2025.12.24 CORNELL UNIVERSITY
  • EP3963326B1 patent drawingFigure 1A
  • EP3963326B1 patent drawingFigure 1A
  • EP3963326B1 patent drawingFigure 1A

AI summary

The present application relates to fibers having a diameter of 1 nm to 10,000 nm, of one or more biocompatible polymers, wherein the polymers have a backbone which includes a positively charged component from a zwitterionic moiety. Additionally, this application discloses an implantable therapeutic delivery system and its method of formation, comprising a housing defining a chamber, wherein said housing is porous and formed from the fibers. Inside of the housing includes a preparation of cells which release a therapeutic agent from the chamber. The implantable therapeutic delivery system can be used in the treatment of diabetes.